Already a member? Login here
By creating an account you agree to our Terms and Conditions, Terms of Use, and Privacy Policy and you understand that by downloading vendor information you are agreeing to share your contact information with that vendor.
ICON Specialty Laboratories (formerly MolecularMD) offers specialty laboratory services to support a variety of therapeutic programs. Our CAP-accredited, CLIA-certified laboratories offer fit-for-purpose, platform agnostic biomarker development services spanning a variety of molecular applications including NGS, PCR and IHC. Our core business focuses on centralized testing services and clinical trial assay and IVD development to support the ongoing needs of biopharma clients. We have developed sensitive and highly reliable protein and molecular assays, designed to detect targets within blood based and solid tumor malignancies. A test menu of CLIA and RUO offerings exist with various diagnostic test types to include SNPs, INDELs, CNVs, translocations and/or transcript levels. Specimen expertise includes formalin-fixed paraffin-embedded tissue (FFPE), bone marrow, fine needle aspirates, core biopsies and peripheral blood.
Our platform-agnostic approach to test development spans the following technology platforms:
Our platform-agnostic approach to test development spans the following technology platforms:
![Genomenon said today it has partnered with Rhythm Pharmaceuticals to create a database of genetic mutations associated with obesity as documented in published studies. Rhythm plans to use the data to better understand rare genetic disorders of obesity. [Visual Mozart/Getty Images]](https://www.insideprecisionmedicine.com/wp-content/uploads/2019/01/1628-218x150.jpeg "Metsera Launches with $290M to Develop Next Generation Weight Loss Products")
